意大利 SISTRA 治疗性血液透析登记处:2023 活动年。

IF 1.4 4区 医学 Q4 HEMATOLOGY Transfusion and Apheresis Science Pub Date : 2024-11-22 DOI:10.1016/j.transci.2024.104037
Giustina De Silvestro , Liviana Catalano , Giuseppe Marano , Vanessa Piccinini , Simonetta Pupella , Angelo Ostuni , Vincenzo De Angelis
{"title":"意大利 SISTRA 治疗性血液透析登记处:2023 活动年。","authors":"Giustina De Silvestro ,&nbsp;Liviana Catalano ,&nbsp;Giuseppe Marano ,&nbsp;Vanessa Piccinini ,&nbsp;Simonetta Pupella ,&nbsp;Angelo Ostuni ,&nbsp;Vincenzo De Angelis","doi":"10.1016/j.transci.2024.104037","DOIUrl":null,"url":null,"abstract":"<div><div>The Italian Registry of Therapeutic Apheresis (IRTA) collects clinical data on patients undergoing therapeutic apheresis procedures throughout the national territory, with the main objective of improving the quality and safety of the care provided to the patient. Given the importance of centralizing the collection and analysis of information on therapeutic apheresis, the National Blood Center (NBC), at the request of the Italian Scientific Society of Hemapheresis and Cellular Manipulation (SIdEM), has included IRTA in the Information System of Transfusion Services (SISTRA), which is the information system of the Ministry of Health for the exchange of data on blood and its derivatives between the Italian Regions and the NBC. This manuscript reports IRTA activity data for 2023 maintaining the general approach introduced in previous manuscripts to facilitate comparison with already published activity data (2020–2022). For each therapeutic apheresis procedure (more than 15) we reported the number of procedures, the number of patients treated, and adverse effects. Furthermore, for each pathology belonging to more than 8 specialized clinical areas we reported the number of procedures, the number of patients treated, the number of patients at first diagnosis and the outcome of the patients. More than 36000 procedures in more than 8500 patients were included in the 2023 database. The aim of the IRTA 2023 activity data is to provide an updated snapshot of the use of therapeutic apheresis in the treatment of human diseases in Italy and a strategic resource for institutions and scientific societies.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 1","pages":"Article 104037"},"PeriodicalIF":1.4000,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Italian registry of therapeutic apheresis in SISTRA: Year of activity 2023\",\"authors\":\"Giustina De Silvestro ,&nbsp;Liviana Catalano ,&nbsp;Giuseppe Marano ,&nbsp;Vanessa Piccinini ,&nbsp;Simonetta Pupella ,&nbsp;Angelo Ostuni ,&nbsp;Vincenzo De Angelis\",\"doi\":\"10.1016/j.transci.2024.104037\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>The Italian Registry of Therapeutic Apheresis (IRTA) collects clinical data on patients undergoing therapeutic apheresis procedures throughout the national territory, with the main objective of improving the quality and safety of the care provided to the patient. Given the importance of centralizing the collection and analysis of information on therapeutic apheresis, the National Blood Center (NBC), at the request of the Italian Scientific Society of Hemapheresis and Cellular Manipulation (SIdEM), has included IRTA in the Information System of Transfusion Services (SISTRA), which is the information system of the Ministry of Health for the exchange of data on blood and its derivatives between the Italian Regions and the NBC. This manuscript reports IRTA activity data for 2023 maintaining the general approach introduced in previous manuscripts to facilitate comparison with already published activity data (2020–2022). For each therapeutic apheresis procedure (more than 15) we reported the number of procedures, the number of patients treated, and adverse effects. Furthermore, for each pathology belonging to more than 8 specialized clinical areas we reported the number of procedures, the number of patients treated, the number of patients at first diagnosis and the outcome of the patients. More than 36000 procedures in more than 8500 patients were included in the 2023 database. The aim of the IRTA 2023 activity data is to provide an updated snapshot of the use of therapeutic apheresis in the treatment of human diseases in Italy and a strategic resource for institutions and scientific societies.</div></div>\",\"PeriodicalId\":49422,\"journal\":{\"name\":\"Transfusion and Apheresis Science\",\"volume\":\"64 1\",\"pages\":\"Article 104037\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2024-11-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Transfusion and Apheresis Science\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1473050224002180\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transfusion and Apheresis Science","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1473050224002180","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

意大利治疗性血液净化登记处(IRTA)在全国范围内收集接受治疗性血液净化手术患者的临床数据,主要目的是提高为患者提供的医疗服务的质量和安全性。鉴于集中收集和分析治疗性血液净化信息的重要性,国家血液中心(NBC)应意大利血液净化和细胞处理科学学会(SIdEM)的要求,将IRTA纳入输血服务信息系统(SISTRA),该系统是卫生部的信息系统,用于意大利各大区与国家血液中心之间交换血液及其衍生物的数据。本手稿报告了 2023 年 IRTA 的活动数据,保持了之前手稿中介绍的一般方法,以便于与已公布的活动数据(2020-2022 年)进行比较。对于每项治疗性血液净化手术(超过 15 项),我们都报告了手术数量、接受治疗的患者人数和不良反应。此外,对于属于 8 个以上专业临床领域的每种病理,我们都报告了手术次数、接受治疗的患者人数、初诊患者人数以及患者的治疗效果。2023 年数据库共收录了 8500 多名患者的 36000 多项手术。IRTA 2023活动数据的目的是提供意大利在人类疾病治疗中使用治疗性无细胞疗法的最新情况,并为医疗机构和科学协会提供战略资源。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
The Italian registry of therapeutic apheresis in SISTRA: Year of activity 2023
The Italian Registry of Therapeutic Apheresis (IRTA) collects clinical data on patients undergoing therapeutic apheresis procedures throughout the national territory, with the main objective of improving the quality and safety of the care provided to the patient. Given the importance of centralizing the collection and analysis of information on therapeutic apheresis, the National Blood Center (NBC), at the request of the Italian Scientific Society of Hemapheresis and Cellular Manipulation (SIdEM), has included IRTA in the Information System of Transfusion Services (SISTRA), which is the information system of the Ministry of Health for the exchange of data on blood and its derivatives between the Italian Regions and the NBC. This manuscript reports IRTA activity data for 2023 maintaining the general approach introduced in previous manuscripts to facilitate comparison with already published activity data (2020–2022). For each therapeutic apheresis procedure (more than 15) we reported the number of procedures, the number of patients treated, and adverse effects. Furthermore, for each pathology belonging to more than 8 specialized clinical areas we reported the number of procedures, the number of patients treated, the number of patients at first diagnosis and the outcome of the patients. More than 36000 procedures in more than 8500 patients were included in the 2023 database. The aim of the IRTA 2023 activity data is to provide an updated snapshot of the use of therapeutic apheresis in the treatment of human diseases in Italy and a strategic resource for institutions and scientific societies.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.60
自引率
5.30%
发文量
181
审稿时长
42 days
期刊介绍: Transfusion and Apheresis Science brings comprehensive and up-to-date information to physicians and health care professionals involved in the rapidly changing fields of transfusion medicine, hemostasis and apheresis. The journal presents original articles relating to scientific and clinical studies in the areas of immunohematology, transfusion practice, bleeding and thrombotic disorders and both therapeutic and donor apheresis including hematopoietic stem cells. Topics covered include the collection and processing of blood, compatibility testing and guidelines for the use of blood products, as well as screening for and transmission of blood-borne diseases. All areas of apheresis - therapeutic and collection - are also addressed. We would like to specifically encourage allied health professionals in this area to submit manuscripts that relate to improved patient and donor care, technical aspects and educational issues. Transfusion and Apheresis Science features a "Theme" section which includes, in each issue, a group of papers designed to review a specific topic of current importance in transfusion and hemostasis for the discussion of topical issues specific to apheresis and focuses on the operators'' viewpoint. Another section is "What''s Happening" which provides informal reporting of activities in the field. In addition, brief case reports and Letters to the Editor, as well as reviews of meetings and events of general interest, and a listing of recent patents make the journal a complete source of information for practitioners of transfusion, hemostasis and apheresis science. Immediate dissemination of important information is ensured by the commitment of Transfusion and Apheresis Science to rapid publication of both symposia and submitted papers.
期刊最新文献
Editorial Board The Italian registry of therapeutic apheresis in SISTRA: Year of activity 2023 Comparison of different concentrations of calcium gluconate added in replacement fluid to maintain ionised calcium levels during therapeutic plasma exchange procedures Mechanistic insights from a pilot exploratory study of the dynamic proteomic changes during plasma exchange in patients with acute liver failure Editorial commentary: The latest viewpoint on a statistical analysis of total analytical errors in diagnostic tools used for quantitative testing of medical devices in transfusion medicine & insights on the development of autoantibody isotypes to the Annexin A1 protein of the neutrophil in association with COVID-19-induced hyperinflammatory processes
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1